970 related articles for article (PubMed ID: 16014598)
1. Androgen deprivation therapy for prostate cancer.
Sharifi N; Gulley JL; Dahut WL
JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
3. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
4. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
7. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
8. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
9. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
10. The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.
Zhao S; Urdaneta AI; Anscher MS
Expert Rev Anticancer Ther; 2016 Sep; 16(9):929-42. PubMed ID: 27464256
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
Isbarn H; Boccon-Gibod L; Carroll PR; Montorsi F; Schulman C; Smith MR; Sternberg CN; Studer UE
Eur Urol; 2009 Jan; 55(1):62-75. PubMed ID: 18945543
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
15. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
Walker LM; Tran S; Robinson JW
Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
[TBL] [Abstract][Full Text] [Related]
18. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
19. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.
Roach M
Cancer; 2014 Jun; 120(11):1620-9. PubMed ID: 24591080
[TBL] [Abstract][Full Text] [Related]
20. Management of complications of androgen deprivation therapy in the older man.
Mohile SG; Mustian K; Bylow K; Hall W; Dale W
Crit Rev Oncol Hematol; 2009 Jun; 70(3):235-55. PubMed ID: 18952456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
